Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study was to evaluate the effects of integrated treatment for patients with a first episode of psychotic illness. We conducted a randomised clinical trial in Copenhagen Hospital Corporation and Psychiatric Hospital Aarhus, Denmark. We included 547 patients with first episode of schizophrenia spectrum disorder, who has not received antipsychotic medication for more than 12 weeks.
Patients were randomised to integrated treatment or standard treatment. The integrated treatment lasted for two years and consisted of assertive community treatment with programmes for family involvement and social skills training. Standard treatment offered contact with a community mental health centre.
We wanted to study the effect on psychotic (hallucinations and delusions)and negative (lack of initiative, apati, blunted affect) symptoms (each scored from 0 to a maximum of 5) at one and two years’ follow-up.
We found that integrated treatment improved clinical outcome and adherence to treatment. The improvement in clinical outcome was consistent at one year and two year follow-ups. We will study further outcome measures such as social network, quality of life, depression and suicidal behaviour.
| Condition | Intervention |
|---|---|
|
Psychotic Disorders Schizophreniform Disorders Schizoaffective Disorder Psychosis, Brief Reactive Schizophrenia, Borderline |
Behavioral: Integrated treatment, family involvement Behavioral: Social skills training |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Randomised Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis |
- Psychotic symptoms at one and two year follow-up
- Negative symptoms at one and two year follow-up
- Adherence at one and two year follow-up
- Depression at one and two year follow-up
- Suicidal behaviour at one and two year follow-up
- Use satisfaction at one and two year follow-up
- Quality of life at one and two year follow-up
| Estimated Enrollment: | 600 |
| Study Start Date: | January 1998 |
| Estimated Study Completion Date: | December 2005 |
Objectives: To evaluate the effects of integrated treatment for patients with a first episode of psychotic illness.
Design: Randomised clinical trial. Setting: Copenhagen Hospital Corporation and Psychiatric Hospital Aarhus, Denmark Participants: 547 patients with first episode of schizophrenia spectrum disorder.
Interventions: Integrated treatment and standard treatment. The integrated treatment lasted for two years and consisted of assertive community treatment with programmes for family involvement and social skills training. Standard treatment offered contact with a community mental health centre.
Main outcome measures: Psychotic and negative symptoms (each scored from 0 to a maximum of 5) at one and two years’ follow-up.
Results: At one year’s follow-up, psychotic symptoms changed favourably to a mean of 1.09 (standard deviation 1.27) with an estimated mean difference between groups of –0.31 (95% confidence interval –0.55 to –0.07, P=0.02) in favour of integrated treatment. Negative symptoms changed favourably with a estimated difference between groups of –0.36 (–0.54 to –0.17, P<0.001) in favour of integrated treatment. At two years’ follow-up the estimated mean difference between groups in psychotic symptoms was –0.32 (0.58 to –0.06, P=0.02) and in negative symptoms was –0.45 (–0.67 to –0.22, P<0.001), both in favour of integrated treatment. Patients who received integrated treatment had significantly less comorbid substance misuse, better adherence to treatment, and more satisfaction with treatment.
Conclusion: Integrated treatment improved clinical outcome and adherence to treatment. The improvement in clinical outcome was consistent at one year and two year follow-ups.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18-45 years of age
- F2 diagnosis in ICD 10
- Address in Copenhagen, Frederiksberg or Aarhus
- Antipsychotic medication not exceeding 12 weeks
- Informed consent
Exclusion Criteria:
Contacts and Locations| Denmark | |
| Bispebjerg Hospital, department of psychiatry | |
| Copenhagen, Denmark, 2400 | |
| Principal Investigator: | Merete Nordentoft, Ph.D. | Bispebjerg Hospital, department of psychiatry, University of Copenhagen |
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00157313 History of Changes |
| Other Study ID Numbers: | OPUS trial |
| Study First Received: | September 8, 2005 |
| Last Updated: | April 25, 2006 |
| Health Authority: | Denmark: National Board of Health |
Keywords provided by Bispebjerg Hospital:
|
Schizophrenia First episode psychosis Psychosocial intervention |
Additional relevant MeSH terms:
|
Psychotic Disorders Mental Disorders Schizophrenia |
Schizotypal Personality Disorder Schizophrenia and Disorders with Psychotic Features Personality Disorders |
ClinicalTrials.gov processed this record on May 16, 2013